The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.

By M. Cordenonsi, F. Zanconato, L. Azzolin, M. Forcato, Antonio Rosato, C. Frasson, Masafumi Inui, Marco Montagner, A. Parenti, A. Poletti and 5 more. Cell, 2011

1,329 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/761a7a6c3d44f5e205cee64aa7a62ead4d35741b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. S. Piccolo
3. Fa-Xing Yu
4. Bin Zhao
5. G. Halder
6. M. Cordenonsi
7. Randy L. Johnson
8. H. Park

In Molecular Biology

1. K. Guan
2. Fa-Xing Yu
3. S. Piccolo
4. Bin Zhao
5. Randy L. Johnson
6. G. Halder
7. Duojia Pan
8. M. Cordenonsi

Citations in the corpus

• The Hippo Signaling Pathway in Development and Disease (2019, background): “Besides an evolutionarily conserved role in promoting cell proliferation and survival, YAP/TAZ are required and sufficient to confer cancer stem cell (CSC) traits (Cordenonsi et al., 2011).”
• The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain (2012, background): “TAZ, a related protein that also is repressed by the Hippo pathway, recently was shown to confer cancer stem cell-like traits in breast cancer cells (31), suggesting that defects in Hippo signaling also play important roles in cancer.”
• Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance (2019, background): “Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.”
• YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. (2014, methodology): “…day, they were plated at very high density on fibronectin-coated chamberslides; cells were fixed after 48 hr. Immunofluorescence was as described in Cordenonsi et al. (2011) using anti-YAP (H-9 sc-271134; 1:200, blocking in goat serum; monoclonal antibody was from Santa Cruz) and anti-TAZ (560235;…”
• The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease (2014, background): “Loss of Scribble, an epithelial basal-lateral domain determinant, from mammary epithelial cells also increases the nuclear abundance and activity of TAZ (Cordenonsi et al., 2011).”
• The biology of YAP/TAZ: hippo signaling and beyond. (2014, background): “At the cell membrane, Scribble serves as adaptor for the Hippo kinases by assembling a complex containing MST, LATS, and TAZ, required for MST-mediated activation of LAST (FIGURE 2) (38).”
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. (2015, positive): “, 2012), and TAZ is required to sustain selfrenewal and the tumor-initiation capacity of breast cancer stem cells (Cordenonsi et al., 2011).”
• Metabolic control of YAP and TAZ by the mevalonate pathway (2014, methodology): “TAZ, which is overexpressed in about 85% of grade-3 breast cancer, has been shown to be a inducer of cancer stem cells traits, metastasis and chemoresistance and its levels correlates with poor clinical outcome (Bartucci et al., 2014; Cordenonsi et al., 2011) (Fig.”
• The Hippo signaling pathway in stem cell biology and cancer (2014, positive): “Moreover, TAZ has been shown to be a key regulator of cancer stem cells (CSCs) in breast cancer [139].”
• YAP/TAZ at the roots of cancer (2016, background): “…in cultured cells in association to YAP/TAZ inhibition by several upstream signals, and these biochemical findings, including some from our own group (Cordenonsi et al., 2011), have been interpreted as Hippo/LATS serving as unique bottleneck/integrator for YAP/TAZ regulation (Meng et al., 2016).”
• The Hippo pathway: regulators and regulations. (2013, background): “Moreover, Scrib also positively regulates the Hippo pathway kinases, and down-regulation of Scrib leads to YAP/TAZ activation (Cordenonsi et al. 2011; Chen et al. 2012).”